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Intermittent claudication is not a limb-threaten-
ing condition. Rather, it is a reflection of an underly-
ing disease process. In most patients, the symptoms
stabilize with risk factor modification alone, and many
patients find that they can function adequately within
their claudication distance. However, in a minority of
patients with claudication, the symptoms progress and
a severe disability can result, which drastically curtails
normal daily activities. In these patients who are self-
selecting, intervention may be regarded as worth-
while. The operations for intermittent claudication
can be conveniently divided into suprainguinal proce-
dures and infrainguinal procedures. The infrainguinal
procedures have been limited in the past to above-
knee bypass grafting with either autologous vein or
prosthetic material. The traditional teaching has been
that, because the natural history of claudication is
benign compared with the life expectancy of the
patient, the worst possible outcome should be the
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Purpose: Infrainguinal reconstruction traditionally has been reserved for patients with
limb-threatening ischemia. Surgery for debilitating claudication, however, has been dis-
couraged as a result of the perceived fear of bypass graft failure, limb loss, and signifi-
cant perioperative complications that may be worse than the natural history of the dis-
ease. In this study, the results of infrainguinal reconstructions for claudication per-
formed during the past 10 years were evaluated for bypass graft patency, limb loss, and
long-term survival rates.
Methods: Data were collected and reviewed from the vascular registry, the office charts,
and the hospital records for patients who underwent infrainguinal bypass grafting for
claudication.
Results: From 1987 to 1997, 409 infrainguinal reconstructions were performed for clau-
dication (9% of all infrainguinal reconstructions in our unit). The patient population
had the following demographics: 73% men, 28% with diabetes, 54% smokers, and an
average age of 64 years (range, 24 to 91 years). Inflow was from the following arteries:
iliac artery/graft, 10%; common femoral artery, 52%; superficial femoral artery, 19%;
profunda femoris artery, 16%; and popliteal artery, 2%. The outflow vessels were the fol-
lowing arteries: 165 above-knee popliteal arteries (40%), 150 below-knee popliteal arter-
ies (37%), and 94 tibial vessels (23%). The operative mortality rate was 0%, and one limb
was lost in the series from distal embolization. The primary patency rates were 62%,
77%, and 86% for above-knee popliteal artery, below-knee popliteal artery, and tibial ves-
sel reconstructions at 4 years, and the secondary patency rates were 64%, 81%, and 90%,
respectively. Cumulative patient survival rates were 93% and 80% at 4 and 6 years as
compared with 65% and 52%, respectively, for infrainguinal reconstructions performed
for limb salvage.
Conclusion: Infrainguinal arterial reconstruction for disabling claudication is a safe and
durable procedure in selected patients. These data indicate that concern for limb loss,
death, and limited life span of the patients with this disease may not be warranted. 
(J Vasc Surg 1999;29:259-69.)
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return to the baseline state of claudication symptoms.
The use of more distal reconstructions in patients for
claudication should be cautiously applied because of
the consequences of graft failure and the possibility of
ensuing limb loss. This is not without good reason. In
some published series,1-4 the reported primary and
secondary 5-year patency rates for femorotibial bypass
grafting for critical ischemia have been 63% to 69%
and 72% to 85%, respectively, with limb salvage rates
of 84% to 92%. However, in one reported series,5
femorotibial bypass grafting was associated with a 26%
failure rate and a 24.4% amputation rate at 30 days
and an overall operative mortality rate of 3.9%. In this
particular series, if the amputations after 30 days were
included, 39 of the 85 reconstructed limbs (46%)
underwent amputation. Such results are not just the
preserve of smaller units. Indeed, one teaching hospi-
tal has reported 36-month secondary patency rates for
tibial bypass grafting of 31% to 51%, but sporadic data
showed improved results that justified a more liberal
approach for patients with claudication.6-10
In Albany, there has been a long tradition of distal
reconstruction for limb salvage.7 In the past two
decades, the techniques and the instrumentation for
distal in situ bypass grafting gradually have evolved.
Our experience with tibial bypass grafting for limb sal-
vage now numbers some 4468 cases, with secondary
patency rates of 91% and 81% at 1 and 5 years, cumu-
lative limb salvage rates of 97% and 85% at 1 and 5
years,8 and an operative mortality rate of 2%. In addi-
tion, we have performed distal bypass grafting on a
further 884 patients with excised vein as a conduit.9
These cases have been performed with an operative
mortality rate of 2% and a limb salvage rate of 95%.
With this background, we began to cautiously extend
the use of distal bypass grafting to patients with clau-
dication whose symptoms had progressed despite a
trial of conservative therapy or whose symptoms
severely curtailed their social or professional activities.
This paper details our experience with all the patients
on our vascular service who have undergone infrain-
guinal reconstruction for claudication.
METHODS
Patients who are seen at our office with symptoms
of intermittent claudication undergo a full clinical
assessment. Pulse volume recordings (PVRs) are
recorded to confirm a diagnosis of chronic vascular
insufficiency or to exclude other causes. The patients
with vascular claudication are advised to alter their
lifestyle habits, and exercise programs are prescribed.
The patients then undergo reassessment every 3 to 6
months. We have the following criteria for operative
intervention: continued progressive deterioration of
claudication distances by history despite risk factor
modification, short distance claudication that severely
curtails normal social and economic activities, and oth-
erwise healthy patients who are severely incapacitated
by their claudication. Possible complications, includ-
ing death, risk of limb loss in the event of graft failure,
and cardiac or wound complications, are stressed.
The standards of reporting used in this paper 
are those suggested by the Society for Vascular
Surgery/International Society for Cardiovascular
Surgery committees in relation to interventional ther-
apies for peripheral vascular disease.10 A computerized
vascular database has been prospectively maintained in
our center since 1982. Details on all patients who have
undergone vascular interventions have been collected.
The basic patient demographic details and the perti-
nent risk factors for vascular disease are entered. All the
operative procedures also are reported. Data on all the
technical aspects of reconstructions are documented,
including operative indication, inflow artery, outflow
artery, vascular conduit, and vein preparation tech-
nique. Because the vein is the preferred conduit in our
center, the reasons as to its nonuse also are logged.
All the patients who undergo vascular recon-
structions have PVRs and duplex scan surveillance of
their vein grafts performed on the first postoperative
day. A PVR and duplex scan surveillance then are
performed on autogenous venous reconstructions at
6 weeks, every 3 months for 12 months, and then
every 6 months after surgery. PVRs with segmental
pressures only were used for follow-up of prosthetic
reconstructions. The improvement of claudication
was determined by history and improvement in non-
invasive vascular laboratory tests.
For the purposes of this study, all the patient
charts also were retrieved from the hospital files. The
following data were extracted: postoperative prob-
lems after hospital discharge, symptom improve-
ment, return to desired level of activity, and recur-
rence of claudication symptoms or disease progres-
sion. We cross-referenced the chart data with the
data from our database to confirm its accuracy.
Further intervention was performed for deteriora-
tion of walking distance by history, vascular labora-
tory testing, and occluded or failed grafts. For pur-
poses of comparison, we retrieved data on all the
patients who underwent infrainguinal bypass graft-
ing for limb salvage from 1987 to 1997.
RESULTS
Of the 4468 infrainguinal bypass grafting proce-
dures that were performed in our unit from 1987 to
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1997, 409 (9%) were for intermittent claudication.
Overall, tibial bypass grafts for claudication accounted
for 2.1% of all the infragenicular bypass grafting pro-
cedures that were performed in our center between
1987 and 1997. The demographics were similar in
those patients who underwent above-knee popliteal
artery, below-knee popliteal artery, and tibial bypass
grafting (Table I). Despite attempts at risk factor mod-
ification, 219 of the 409 patients (54%) admitted to
smoking at the time of surgical admission. However,
when questioned more closely, 86% of the patients
admitted to substantial cigarette consumption. The
mean follow-up time for all the patients was 52
months (range, 1 to 166 months).
One hundred sixty-five (41%) of the 409 proce-
dures that were performed were femoral to above-
knee popliteal bypass grafts. All inflow arteries, out-
flow arteries, and vascular conduits are listed in Table
II. Of the 165 above-knee popliteal bypass grafting
procedures that were performed, most (149/165 or
90%) were carried out with expanded polytetrafluo-
roethylene (ePTFE) grafts. An ePTFE graft was used
in the above-knee position when the ipsilateral
greater saphenous vein was not available in 101
patients and when the vein was spared in 48 patients.
Seven patients (4%) underwent bypass grafting with
in situ vein, and nine (6%) with reversed vein. Among
the 150 below-knee popliteal bypass grafts, in situ
vein was preferred in 120 (80%), with excised vein
used in 26 (17%) and ePTFE in four (3%). In the tib-
ial bypass graft group, 70% of the patients underwent
in situ saphenous vein reconstructions and 30% of
these procedures were performed with excised vein.
Of the 409 patients who underwent infrainguinal
reconstruction, 22.1% had previously undergone
some form of procedure for aortoiliac occlusive dis-
ease. These procedures were performed at a mean of
29 months (standard deviation, ± 56.5 months)
before the bypass grafting operation. In most of the
cases (9.8% of the overall patient group), the inflow
procedure was an aortobifemoral bypass grafting, and
in 5.4% of all patients, this procedure was followed by
a common iliac artery balloon angioplasty. Iliofemoral
bypass grafting or aortoiliac endarterectomy was car-
ried out in 6.3% of the patients, and femorofemoral
crossover in 0.3%.
There were no operative deaths among the
patients who underwent bypass grafting for inter-
mittent claudication. There was one instance of limb
loss, as a result of distal embolization, for an ampu-
tation rate of 0.25%. This loss occurred in a patient
who underwent above-knee femoral popliteal bypass
grafting with ePTFE. One patient (0.25%) required
a return to the operating room for control of bleed-
ing. Wound infections developed in 12 patients (3%)
and delayed hospital discharge. Of these infections,
five occurred in patients who underwent above-knee
ePTFE bypass grafting, three in the below-knee
bypass graft group, and four in the patients for tibial
bypass grafting. There were two graft infections
(0.5%), both with ePTFE reconstructions. There
were eight early graft failures—one (0.6%) in the
group of 165 ePTFE above-knee bypass grafts and
seven (4%) in the group of 150 below-knee bypass
grafts (all vein), but none in the group of 94 tibial
artery bypass grafts. However, overall, early (<30
days) operative reintervention was necessitated in 14
limbs. Of these, four were simple fistula ligations
performed with local anesthesia and two were pro-
phylactic revisions of vein grafts. Of the remaining
eight bypass graft interventions, those that were
early failures, one was a revision of an above-knee
popliteal bypass graft and seven were salvages of
below-knee popliteal grafts. Intervention was neces-
sitated between 30 days and 1 year on 24 limbs. The
indication in 13 of these limbs was further claudica-
tion, with rest pain or nonhealing ulcers occurring in
nine patients (one at 30 days, six at 6 months, and
two at 1 year) and acute ischemia in one patient (14
days). Of the eight patients who were late sympto-
matic, three had progression of the disease and five
had deterioration of the graft (two prosthetic, three
vein). The remaining patient was asymptomatic but
required fistula ligation with local anaesthesia.
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Table I. Demographic details by reconstruction type
No. of AK popliteal bypass grafts No. of BK popliteal bypass grafts No. of tibial bypass grafts
Men 113 (68.48%) 111 (74%) 74 (78.72%)
Women 52 (31.52%) 39 (26%) 20 (21.28%)
Diabetes 50 (30.3%) 37 (24.67%) 28 (29.79%)
Smoking 94 (56.97%) 80 (53.33%) 45 (47.87%)
Average age (years) 63 63 66
Age range (years) 35 to 89 24 to 87 34 to 91
AK, Above-knee; BK, below-knee.
The primary patency rates for all the above-knee
bypass grafts at 1 year, 3 years, and 5 years were 82%,
70%, and 48%, respectively (Table III; Fig 1). For the
below-knee popliteal bypass grafts, the primary
patency rates were 86%, 77%, and 70%, and, for tib-
ial artery bypass grafts, were 86%, 86%, and 79%. The
secondary patency rates for the above-knee bypass
grafts were 83%, 72%, and 50% at 1, 3, and 5 years
after surgery. The secondary patency rates for the
below-knee popliteal reconstructions were 90%, 81%,
and 78%, and, for tibial artery bypass grafts, were
92%, 90%, and 83%. The primary patency rate for the
comparison of a prosthetic above-knee popliteal and
below-knee vein reconstructions approached statisti-
cal significance at 30 days and 1 year (P > .01).
Otherwise, there was no statistically significant dif-
ference between these groups (Table III; Fig 2).
The cumulative patient survival rate for patients
who underwent bypass grafting for claudication was
100% at 30 days (Table IV), and, at 1 year, 3 years, and
5 years, the cumulative survival rates were 98%, 93%,
and 86%, respectively. When the rates were stratified by
procedure, the cumulative survival rates at 5 years were
similar for above-knee, below-knee, and tibial artery
bypass grafting (Table IV). By comparison, the overall
cumulative survival rates at 1 and 5 years for 4059
patients who underwent surgery for limb salvage were
significantly worse at 86% and 59% (P < .05).
Of the 409 procedures that were performed pri-
marily for intermittent claudication, 75 (18.3%)
necessitated a second operative procedure. Second
surgeries were carried out at a mean of 23 months
(standard deviation, ± 37.5 months) after the initial
operation. There were a further 5.4% of the patients
in whom successful bypass grafting surgery failed to
completely resolve the claudication but who did not
require further intervention. Of the 75 limbs that
necessitated second operations, in 50%, the indica-
tion was recurrence of claudication. In 27.9%, rest
pain or nonhealing ulcer was the main symptom.
Acute ischemia mandated reintervention in 7.3% of
the patients. Of the 75 second procedures, 34 were
bypass grafts to the below-knee popliteal artery, 21
were bypass grafts to the tibial arteries, and five were
redo above-knee bypass grafts. The remaining 13
procedures were ligation of fistulae and revision of
graft stenoses and two patients who underwent
thrombolysis of thrombosed grafts.
The 75 second procedures were stratified accord-
ing to primary operative procedure. Of those patients
who underwent above-knee popliteal reconstruc-
tions, 22.5% required second procedures. Of those
patients whose primary procedure was a below-knee
popliteal bypass grafting, 14.5% required a further
procedure, and 9.6% of those patients who under-
went tibial artery bypass grafting needed a second
operation. The risk of further surgery was signifi-
cantly greater (P < .005, with c 2 test) for patients
who underwent above-knee popliteal bypass grafting
as their primary operation versus below-knee
popliteal or tibial bypass grafting. There were no sig-
nificant differences in incidence rates of further
surgery between those patients who underwent tibial
versus below-knee popliteal bypass grafting.
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Table II, A. Inflow arteries
No. of AK popliteal bypass grafts No. of BK popliteal bypass grafts No. of tibial bypass grafts
Iliac artery/graft 23 10 8
Common femoral artery 119 64 31
Superficial femoral artery 14 32 32
Profunda femoris artery 9 41 16
Popliteal artery 0 3 7
AK, Above-knee; BK, below-knee.
Table II, B. Outflow arteries
No. of vessels
Above-knee popliteal artery 165
Below-knee popliteal artery 150
All tibial vessels 94
Anterior tibial artery 15
Posterior tibial artery 37
Peroneal artery 43
Table II, C. Conduits
No. of vessels





The data on amputation and risk of disease pro-
gression in patients with peripheral vascular occlu-
sive disease are well known but bear reiteration.
Lower extremity claudication as a result of peripher-
al arterial occlusive disease affects approximately
10% of the population of the United States at more
than 70 years of age.11 It affects 1% to 2% of the
population aged 37 to 69 years and is five times
more common in patients with diabetes.12 Despite
the large numbers of patients with some degree of
peripheral vascular disease, “only” 100,000 opera-
tions are performed annually for lower extremity
ischemia.13 Obviously, most of patients undergo
conservative treatment. Indeed, in 1983, the US
Surgeon General estimated that only 10% of the
patients with claudication required surgical interven-
tion.14
In patients who do not undergo treatment for
claudication, disease progression to the stage at
which amputation is necessitated is a rare event. In
the Framingham study, only 1.6% of the patients
with claudication who were followed for 8.3 years
required amputation.15 Boyd16 prospectively fol-
lowed 1440 patients with intermittent claudication
and found that, after 10 years, 12.2% required
amputation. The amputation rates in other studies
have been consistently low at 0.5% per annum.17
Approximately 80% of the patients who are seen
with claudication will either have a stabilized condi-
tion or, with modification of their risk factors and
adherence to an exercise program, actually improve
their walking distance. Indeed, the intervention
rates for all the patients with claudication is only 5%
per annum.18 In those patients in whom disease pro-
gression occurs, cigarette smoking has repeatedly
been identified as the most consistent adverse risk
factor.19 Progression is also more common in those
patients with more severe disease at the time of ini-
tial presentation and in patients with diabetes.20 In
the face of these facts, compelling arguments are
needed to support the use of any intervention at all
when a patient is seen with symptoms of intermit-
tent claudication. It follows that any intervention
must not result in a limb loss rate of more than 0.5%
per annum. However, the adoption of such a strict
utilitarian approach ignores the broader aspects of
the management of claudication. For a minority of
such patients, living within the strict confines of a
limited claudication distance represents a consider-
able physical disability and mental burden compara-
ble with other chronic degenerative disease process-
es. In addition, cardiac rehabilitation associated with
coronary artery disease may be hindered because of
claudication.
Cost-utility analysis and quality of life measure-
ments have been extensively used to assess surgical
outcomes and make decisions about resource alloca-
tion. In the management of chronic diseases, the out-
comes are measured in units that relate to a patient’s
level of well-being or “utility-based” units.21 These
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Fig 2. Comparison of secondary patency rates for limb
salvage and claudication.
Fig 1. Comparison of primary patency rates for limb sal-
vage and claudication.
Fig 3. Comparison of cumulative patient survival rates
for limb salvage and claudication.
units are calculated by estimating the total life years
gained from a procedure and weighing each year to
reflect the quality of life in that year. Studies from sev-
eral European centers22-26 and from the Scottish
Vascular Audit group27 suggest that intermittent clau-
dication impairs the quality of life in all aspects and
that this degree of impairment seems to correlate with
the degree of ischemia. In addition, it has been shown
that clinicians often fail to appreciate the impact of
impaired walking distance on their patients’ quality of
life. Furthermore, intervention in the form of balloon
angioplasty or surgical revascularization can result in
significant improvements in quality of life measures.28
Data from this country29 reinforce this impression by
suggesting that the functional benefit of revascular-
ization for claudication cannot be gauged by objective
outcome measures alone, such as ankle-brachial
indices, and that functional endpoints may be more
important when evaluating the results of bypass graft
surgery.
Other investigators have suggested that intermit-
tent claudication may be more pernicious than pre-
viously appreciated.30 Evidence from United
Kingdom studies suggests that intermittent claudica-
tion represents repeated cycles of ischemia and
reperfusion with resultant neutrophil activation and
systemic vascular injury.31,32 This suggestion has
been supported by experimental animal models that
showed systemic increases in leukocyte-endothelial
adhesion and vascular permeability to albumin after
subtotal ischemia in a single limb.33 This has been
evoked as a possible factor in the higher than expect-
ed cardiovascular mortality rate among patients with
claudication. It has also been suggested that such
systemic responses can be altered with surgical revas-
cularization.30
Although many studies attest to the effectiveness
of structured walking programs in improving claudi-
cation distances,34-36 there have been few studies that
directly compared the programs with surgical revas-
cularization. The exception was a Swedish study37 in
1989 that randomly allocated 75 matched patients
with claudication to either supervised physical train-
ing, surgery alone, or exercise plus surgery. The
surgery was the most effective therapy but was asso-
ciated with more complications. The addition of
training to surgery improved the results even further.
The authors concluded that the improvement in their
surgically-treated group was probably a result of sig-
nificantly higher calf blood flow and ankle pressures
after the operation. It is probably noteworthy that
compliance in the supervised training group in this
study was 84%. The compliance rates for unsuper-
vised training are probably much lower.
Despite these arguments that support the surgical
revascularization of the patient with claudication, we
estimate that only 10% to 15% of the patients with
claudication who are seen at our center undergo
surgery. The vast majority continue to undergo con-
servative treatment. Although 409 patients with clau-
dication undergoing infrainguinal bypass grafting
may at first sight seem a large number, it still only
represented 9% of all the infrainguinal reconstruc-
tions that were performed in our unit in a 10-year
period. However, perhaps the most striking aspect of
our experience is not that we carried out 409 infrain-
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Table III. Bypass grafts for claudication
Primary Total no. of 30 days
patency bypass grafts (±SE) Year 1 (±SE) Year 2 (±SE) Year 3 (±SE) Year 4 (±SE) Year 5 (±SE) Year 6 (±SE)
All AK popliteal 165 0.981 0.818 0.722 0.702 0.619 0.478 0.478 
bypass grafts (±0.01) (±0.03) (±0.05) (±0.06) (±0.07) (±0.08) (±0.10)
All BK popliteal 150 0.929 0.863 0.831 0.767 0.767 0.698 0.608
bypass grafts (±0.02) (±0.03) (±0.04) (±0.06) (±0.07) (±0.08) (±0.09)
All tibial bypass 94 0.921 0.859 0.859 0.859 0.859 0.790 0.790
grafts (±0.03) (±0.04) (±0.05) (±0.06) (±0.07) (±0.10) (±0.10)
Secondary Total no. of 30 days
patency bypass grafts (±SE) Year 1 (±SE) Year 2 (±SE) Year 3 (±SE) Year 4 (±SE) Year 5 (±SE) Year 6 (±SE)
All AK popliteal 165 0.981 0.826 0.743 0.723 0.642 0.503 0.503
bypass grafts (±0.01) (±0.03) (±0.05) (±0.06) (±0.07) (±0.08) (±0.10)
All BK popliteal 150 0.951 0.903 0.856 0.814 0.814 0.780 0.694
bypass grafts (±0.02) (±0.03) (±0.04) (±0.05) (±0.06) (±0.07) (±0.09)
All tibial bypass 94 0.966 0.920 0.895 0.895 0.895 0.826 0.826
grafts (±0.02) (±0.03) (±0.05) (±0.05) (±0.06) (±0.09) (±0.11)
SE, Standard error of the mean; AK, above-knee; BK, below-knee.
guinal bypass grafting procedures for claudication
but that 150 of these were below-knee bypass grafts
and that 94 tibial artery bypass grafting procedures
were performed. Although 94 tibial artery bypass
grafting procedures were performed in the last 10
years for intermittent claudication in our unit, these
represent only 2.1% of all the infrainguinal revascu-
larizations that were performed during this time.
This would suggest some degree of caution in per-
forming such bypass grafts in the patient for nonlimb
salvage. It is gratifying that these 94 patients had no
mortalities and no amputations and that the vast
majority had an immediate relief of symptoms.
The cumulative secondary patency rates at 5 years
for below-knee popliteal and tibial bypass grafts were
78% and 83%. The cumulative 5-year survival rates
were 95% for below-knee popliteal bypass grafts for
claudication and 79% for tibial bypass grafts.
Together, these would imply a significant contribu-
tion to the quality of life of these individuals.
Overall mortality (0%) and limb loss (0.25%)
rates for the infrainguinal reconstructions in this
study compare with those from other studies that
focus on surgical reconstruction for intermittent
claudication. Our single amputation was in a patient
who underwent above-knee popliteal reconstruction
as a result of distal embolization. Although unfortu-
nate, a limb-loss rate of 1/165 (0.6%) for above-
knee popliteal reconstruction is comparable with
reports from other centers. However, there were no
early or late amputations in the below-knee popliteal
or tibial artery bypass graft group. This is similar to
the experience of the Brigham group6 and would
tend to reinforce their impression that the concerns
about limb loss may be overstated. Our amputation
rate in this series is also in keeping with the expect-
ed amputation rates from historical studies in
patients with claudication.15,16
In this series, we reviewed our experience with
vascular reconstruction for intermittent claudica-
tion. Philosophically, one might question the wis-
dom of performing potentially harmful procedures
for what is a pathologically benign disease process,
especially when 18% of those interventions necessi-
tated second procedures. Although it is disingenu-
ous to compare different surgical procedures, the
concept of performing major surgery for chronic
degenerative diseases that impair patient mobility
and sense of well-being is not novel. The results
from national and regional hip and knee reg-
istries40,41 and from the Veteran Administrations
Affairs studies42 show operative mortality rates for
total hip and total knee replacements of 0% to 1%,
with revision rates of 9% to 15% in 5 years, morbid-
ity rates of 1% to 3%, and cumulative 5-year survival
rates of 90% to 95%—almost exactly the rates in this
series of patients.
In summary, infrainguinal and infragenicular
bypass grafting procedures, particularly with autoge-
nous veins, are valid treatment options in selected
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Table IV. Cumulative patient survival rates
Bypass grafts for Total no. of 30 days
claudification bypass grafts (±SE) Year 1 (±SE) Year 2 (±SE) Year 3 (±SE) Year 4 (±SE) Year 5 (±SE) Year 6 (±SE)
All bypass grafts 409 1.000 0.978 0.958 0.931 0.931 0.863 0.797
(±0) (±0.01) (±0.01) (±0.02) (±0.03) (±0.04) (±0.06)
All AK popliteal 165 1.000 0.982 0.982 0.906 0.906 0.802 0.802
bypass grafts (±0) (±0.01) (±0.02) (±0.04) (±0.05) (±0.08) (±0.10)
All BK popliteal 150 1.000 0.970 0.953 0.953 0.953 0.953 0.798
bypass grafts (±0) (±0.01) (±0.03) (±0.03) (±0.03) (±0.04) (±0.08)
All tibial bypass 94 1.000 0.984 0.931 0.931 0.931 0.793 0.793
grafts (±0) (±0.01) (±0.04) (±0.04) (±0.05) (±0.09) (±0.11)
Bypass grafts for Total no. of 30 days
limb salvage bypass grafts (±SE) Year 1 (±SE) Year 2 (±SE) Year 3 (±SE) Year 4 (±SE) Year 5 (±SE) Year 6 (±SE)
All bypass grafts 4059 0.961 0.858 0.778 0.711 0.648 0.587 0.515
(±0.003) (±0.01) (±0.01) (±0.01) (±0.01) (±0.02) (±0.02)
All AK popliteal 493 0.953 0.857 0.777 0.729 0.653 0.625 0.539
bypass grafts (±0.01) (±0.02) (±0.03) (±0.04) (±0.04) (±0.05) (±0.06)
All BK popliteal 840 0.979 0.889 0.813 0.726 0.667 0.619 0.568
bypass grafts (±0.005) (±0.01) (±0.02) (±0.02) (±0.03) (±0.03) (±0.03)
All tibial bypass 2726 0.957 0.849 0.767 0.705 0.642 0.571 0.492
grafts (±0.004) (±0.01) (±0.01) (±0.01) (±0.02) (±0.02) (±0.02)
SE, Standard error of the mean; AK, above-knee; BK, below-knee.
patients with claudication who warrant operative
intervention. Such procedures can be performed
safely with low morbidity rates and no mortalities.
Tibial artery bypass grafting is a safe option in the
patient with claudication, and the concerns about
amputation are probably overstated. Nonetheless,
such distal reconstructions for intermittent claudica-
tion may be best reserved for the patients with auto-
genous veins in units with a large experience of infra-
geniculate bypass grafts and acceptable results for
limb salvage.
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Dr Lloyd M. Taylor, Jr (Portland, Ore). The Albany
group has asked an important question about infrainguinal
bypass graft surgery for claudication—namely, is it worth
the risk? They retrospectively reviewed 409 procedures per-
formed for this indication during 10 years. Patients were
selected if nonoperative therapy failed to prevent worsen-
ing and if the symptoms severely curtailed normal social
and economic activities. Although more specific indications
for operation were not given, the procedures for claudica-
tion only represented 9% of the vast total of more than
4500 infrainguinal bypass graft operations performed. This
fact alone indicates to me that their indications for surgery
were probably appropriately conservative.
The authors clearly have described the risks of the
surgery. No one died during surgery. The performance of
409 consecutive vascular reconstructions of any type with-
out an operative death is noteworthy and indicates appro-
priate patient selection and skillful anesthetic and surgical
care. One patient required an amputation because of com-
plications, eight grafts failed acutely and two became
infected, and 75 grafts became occluded during follow-up.
By my count, this means that 86 of the 409 patients, or
21%, were harmed by the surgery, some severely. We have
no information in this report about how many patients had
long-term side effects, including chronic incisional pain,
saphenous nerve pain, and edema. We do not know how
many patients required long-term medical treatment for
pain control, stockings, or other devices to control edema.
It is not an exaggeration to say that the price for the
improved walking ability in some patients may be a limb
that is chronically uncomfortable or even painful at rest.
Unfortunately, we also have no information that
allows us to determine the benefit of the surgery in this
report. The patency rate of the repairs was admirably high,
as we would expect from these surgeons whose experience
and expertise are widely recognized. However, intermit-
tent claudication is a functional problem. All the patients
in this series underwent operation because their walking
ability was impaired. This report does not tell us whether
the expertly performed surgery relieved the claudication.
This evaluation can only be assessed in functional terms.
To answer the question posed in the title—namely, is
infrainguinal bypass grafting for claudication worth the
risk?—the authors need to answer the following three
questions:
1. How many patients had postoperative improvement
in their walking ability, and what was the magnitude of the
improvement or the lack thereof? 
2. For those patients whose walking ability improved,
was this improvement lessened by the inescapable side
effects of the surgery? 
3. Finally, for each patient, what was the answer to the
simple question: If you had it to do over again, knowing
what you do about the outcome of the operation, would
you elect to have the surgery? 
When we know the answers to these questions, then
we will know whether infrainguinal bypass grafting for
claudication is worth the risk. At present, on the basis of
the information in this study, we do not.
Thank you.
Dr R. Clement Darling III. I would like to thank Dr
Taylor for his insightful comments. Those are all excellent
questions.
When we first looked at our database, I truly expected
to find about a 2% mortality rate and I expected to find
more limb loss. We did not go into this trying to prove a
point. We went into this data evaluation essentially to see
whether we could come up with a better algorithm and a
better method of telling our patients what truly to expect
from this operation.
Most of the questions that were posed to me by Dr
Taylor can only be answered through a prospective study,
especially a study that involves some kind of quality-of-life
evaluation. One of our coauthors John Byrne, who
worked extremely hard on this, went back and checked all
the 409 charts of the patients who had undergone opera-
tion, partially to corroborate the data that we had derived
from the registry and also to see whether there was any
improvement in pulse volume recordings. There was
improvement in the pulse volume recordings in 95% of the
DISCUSSION
patients. But whether that was translated into better walk-
ing distance or better symptomatic relief from their debil-
itating claudication, I really do not have that data. And I
think the only way to evaluate that is by judging it
prospectively.
As far as postoperative complications, there are always
long-term sequelae, such as leg swelling and some inci-
sional pain. Again, all the data we had did not show that
that was a significant problem in this patient population,
but, in a retrospective study, I do not think you can truly
rely on that data. 
Dr Anthony M. Imparato (New York, NY). The
authors have reported that at worst as many as one out of
three, and at best one out of 10, patients with claudication
who are subjected to bypass grafting procedures will either
have had failure of their bypass grafts during a 4-year fol-
low-up period or will have required another operation.
They also report that a considerable number of the
patients’ conditions were made worse. These results hard-
ly indicate that the procedures were durable, especially
because they were done for cosmetic reasons, claudication,
which rarely indicates imminent, or early or ever limb loss.
Nonoperative treatment may be effective for decades. The
implication they offer is that more patients with claudica-
tion should undergo operation because the operation
could be done with less than catastrophic results.
Although not fully in control of the new pathologic
processes set in motion by mechanical intervention on
arteries of any type, I can do it, therefore, I shall do it. Will
you join me?
The questions I have are as follows: 
What is disabling claudication? Were the patients reas-
sured before surgery that claudication does not equate
with limb loss? We have found that when the patients are
thus reassured, the claudication ceases to be disabling and
operations are less attractive to them. 
Did the patients stop smoking before surgery? What
was the fate of those patients whose grafts failed and could
not be retrieved as regards to limb-threatening ischemia?
And did any amputations result from these failures?
We must guard against the attitude expressed by some
that if the community of skilled vascular surgeons will not
operate on patients with claudication, there are others less
skilled and less knowledgeable about vascular diseases who
will intervene with less-effective techniques. We also must
guard against giving these interventionists the data that
will permit them to say, if the vascular surgeons can do it,
so can we.
I strongly suggest that the data presented by the
authors do not justify their implied conclusion that a more
aggressive posture towards operating on patients with
claudication is indicated. Rather the reverse seems more
reasonable. They may be widely quoted to the detriment
of the large community of patients with claudication
whose disease can be quite successfully managed nonoper-
atively with multiple decades of follow-up examination.
And only the rare patient with claudication truly requires
an operation. Thank you.
Dr Darling. Thank you, Dr Imparato. I agree with
your point that everybody should be cautious when
approaching distal reconstruction for patients with claudi-
cation. All of us, I think, in our group have been consis-
tent in telling our patients that they had about a 2% chance
of death from the operation and a 5% chance of a major
complication. We also assured the patients of the benign
nature of the natural history of the disease. We talked to
them, tried to adjust their risk factors, and did not imply
that an aggressive approach to revascularization was the
end-all and cure-all for their walking problems.
However, still faced with these data, we gave the
patients the option of either surgery or no surgery. None
of these patients were brought in immediately from the
office or immediately after the first evaluation for surgery.
The tone of the paper is not necessarily that all patients
should have distal reconstructions for claudication or that
we have a reasonable mortality/morbidity and patency
rate from this operation and therefore we should do it. I
think that what we tried to say with this paper and with
these data is that now you can go to your patients and tell
them there probably will be about a 20% chance of being
reoperated on in the long term. They will probably not die
from the operation, and they probably will not lose their
leg, but they will have to be followed up probably for their
lifetime and they will have a chance of going back to the
operating room, which is not insignificant.
As far as what is debilitating claudication, this is a sub-
jective diagnosis that the patient describes to you. A wise
clinician sometimes will walk their patient around and see if
they do have pain in their legs when they walk. You obvi-
ously have to distinguish between neurogenic claudication
and other forms of claudication as opposed to vasculogenic.
Obviously, we try to get our patients to stop smoking,
but that just does not always happen. We advise them, we
preach to them, and we tell them that the chance of reop-
erations is much higher if they continue smoking. We do
not refuse to operate on them solely because of their
smoking.
Dr David C. Brewster (Boston, Mass). I congratulate
you and your group on your fine results, which appear to
support your conclusions. I wonder if you could elaborate
on decision making, because I think there is still a lot of
judgment involved here. First of all, the anticipated bene-
fit in such patients generally assumes prolonged survival
rates or anticipated survival rates. Say a little bit more
about risk stratification in this regard if you will.
Secondly, Dr Linton and your father always insisted
that patients, particularly with claudication, stop smoking.
Would you agree with that as a requirement before the
surgery is undertaken?
And thirdly, because your results do appear to empha-
size the importance of a vein in terms of prolonged function
of these bypass grafts, do you do anything other than clini-
cal examinations to evaluate the vein in advance of surgery? 
Dr Darling. Thank you, Dr Brewster. The history of
Massachusetts General Hospital in distal reconstruction
has obviously been well recognized.
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We try to dictate to the patients that they stop smok-
ing. There are few ways, short of measuring their car-
boxyhemoglobin levels, to assure that they actually are
changing or have changed their risk factors in any positive
way. We have not adopted a policy, as I mentioned, of
refusing to operate on these patients solely because they
are smokers.
To answer your last question about venous anatomy,
all the patients who underwent distal reconstructions elec-
tively will undergo venous duplex scanning to evaluate
their vein. If the vein is of bad quality and if they have an
above-knee popliteal segment, then we will probably use a
prosthetic to above the knee. These patients did have a sta-
tistically significant increased risk of having a second oper-
ation; however, there were no limb losses that occurred as
a result of the occlusion of those bypass grafts. And I do
not think we have answered the question as to whether
one extends the length of the patient’s ability to undergo
bypass grafting by performing a prosthetic bypass graft
first and then a vein graft later. There is a lot of intragroup
prejudice as to what operation is preferred. Some would
like to do a more “definitive” operation, such as an in situ
venous reconstruction to the below-knee popliteal arter-
ies, and others are more amenable to doing an above-knee
prosthetic bypass grafting procedure.
As far as patient selection, again, we tried to have our
patients undergo evaluation to make sure that they were
adequate cardiac risks for undergoing this type of opera-
tion. We only perform angiography or any invasive proce-
dure if we think a patient is an adequate surgical candidate,
and then we proceed if they have what we consider rea-
sonable anatomy.
Dr Richard P. Cambria (Boston, Mass). My comments
will echo those of Dr Taylor. Two years ago, before the
Annual Meeting of the New England Society for Vascular
Surgery, we presented our results with surgical treatment
for claudication. The principal endpoint in our study was
patient satisfaction. And the question posed by Dr Taylor
for the patients (ie, would you do it again?) was indeed an
important part of that questionnaire. In assessing those
results, we found that 80% of the patients were quite satis-
fied with their outcome. In looking at the variables associ-
ated with the failure of patient satisfaction, there was a
strong trend against infrainguinal revascularization as
opposed to inflow reconstruction. On that basis, we have
continued to maintain an extremely conservative posture
toward recommending infrainguinal revascularization for
claudication. Other variables that predicted an unsatisfac-
tory outcome were diabetes and an age of more than 70
years. Similar to your study, we demonstrated favorable
graft patency and late survival rates. However, as empha-
sized by Dr Taylor, that is somewhat beside the point.
Dr Anthony D. Whittemore (Boston, Mass). I have a
brief question. You followed your vein grafts diligently
with duplex ultrasound scan every 3 months during the
first year. You did so in spite of the fact that you probably
were not getting paid for all of them, and yet you did not
do so with your expanded polytetrafluoroethylene grafts.
The reason that you followed the vein grafts is because you
cannot rely on the pulse volume recordings or the hemo-
dynamic parameters. We know full well that at least 50% of
the individuals with hemodynamically significant lesions
have absolutely normal hemodynamic parameters. Do you
think this represents an opportunity for improvement?
Could you possibly have detected expanded polytetrafluo-
roethylene grafts failing at the distal anastomosis, and
could you have avoided those poor results with that group? 
Dr Darling. Thank you, Dr Whittemore. We have not
had an extensive experience with the use of duplex scan in
evaluating prosthetics. What we really want to find out
when we follow up the prosthetics is whether there is an
inflow and outflow lesion. We do not have to worry about
the lesions intrinsic in the expanded polytetrafluoroethyl-
ene grafts. So, we found the pulse volume recording to be
a relatively reliable indicator as far as diagnosing these
lesions. We have not been as aggressive, as you noted, in
going for secondary patency for patients who have had
prosthetic reconstructions. 
Dr Mark R. Nehler (Denver, Colo). There are about
10 different randomized studies that show that monitored
exercise programs are effective in treating claudication and
that you can double and triple walking distances. Despite
those studies, there are currently no third-party payors who
will pay for the studies. This is where most of our efforts
should be directed. Zyban (bupropion hydrochloride;
Glaxo Wellcome, Inc, Research Triangle Park, NC) is
approved by the Food and Drug Administration for smok-
ing cessation. Carnitine and Cilastazol are basically in the
wings awaiting approval. I think these areas are where our
efforts should be directed.
Dr Darling. Thank you. I think you make an excellent
point. We actually are trying to embark on a study where
we evaluate claudication by giving the patient a standard-
ized regime in a physical therapy practice to evaluate their
walking distance and to see if improvement is greater
when the results are compared with patients who undergo
a self-designed exercise program. As you know, you can
tell your patients, go out and walk as much as you can and
continue to walk through your pain. However, nobody
really knows, just like the smoking, if they are really doing
this constantly. Then, when the patients return 3 to 6
months later, they may say that “I tried it all I could. I
have not walked any better, and I really want something
done. This is debilitating.”
We have tried the different methods of getting
patients to quit smoking cigarettes. And I agree, much of
our efforts should be in preventive medicine as much as
performing distal reconstructions for this disease process.
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